NL7308048A - - Google Patents

Info

Publication number
NL7308048A
NL7308048A NL7308048A NL7308048A NL7308048A NL 7308048 A NL7308048 A NL 7308048A NL 7308048 A NL7308048 A NL 7308048A NL 7308048 A NL7308048 A NL 7308048A NL 7308048 A NL7308048 A NL 7308048A
Authority
NL
Netherlands
Application number
NL7308048A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NL7308048A publication Critical patent/NL7308048A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NL7308048A 1972-07-01 1973-06-08 NL7308048A (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6630172A JPS5512435B2 (cs) 1972-07-01 1972-07-01

Publications (1)

Publication Number Publication Date
NL7308048A true NL7308048A (cs) 1974-01-03

Family

ID=13311838

Family Applications (1)

Application Number Title Priority Date Filing Date
NL7308048A NL7308048A (cs) 1972-07-01 1973-06-08

Country Status (15)

Country Link
US (1) US3925357A (cs)
JP (1) JPS5512435B2 (cs)
AT (1) AT325206B (cs)
AU (1) AU469986B2 (cs)
BE (1) BE801588A (cs)
CA (1) CA996548A (cs)
CH (1) CH573435A5 (cs)
CS (1) CS168036B2 (cs)
DE (1) DE2332840A1 (cs)
FR (1) FR2190414B1 (cs)
GB (1) GB1386566A (cs)
HU (1) HU166029B (cs)
NL (1) NL7308048A (cs)
PL (1) PL92969B1 (cs)
SE (1) SE402916B (cs)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522148U (cs) * 1978-07-29 1980-02-13
SI1757606T1 (sl) * 2001-02-24 2009-10-31 Boehringer Ingelheim Pharma Ksantinski derivati za uporabo kot zdravila kot tudi postopek za njihovo pripravo
US20030171424A1 (en) * 2002-03-07 2003-09-11 Lin Ai J. Intravenous formulation of artelinic acid for treatment of severe and complicated malaria
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
JP5769966B2 (ja) * 2007-08-17 2015-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｆａｂ関連疾患治療用プリン誘導体
PE20140960A1 (es) * 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
WO2010018217A2 (en) * 2008-08-15 2010-02-18 Boehringer Ingelheim International Gmbh Organic compounds for wound healing
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
MX2011006713A (es) 2008-12-23 2011-07-13 Boehringer Ingelheim Int Formas salinas de compuesto organico.
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CA2782179C (en) 2009-11-27 2020-06-23 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
EP2566469B1 (en) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Combination therapy
ES2953123T3 (es) 2010-06-24 2023-11-08 Boehringer Ingelheim Int Terapia para la diabetes
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
KR102391564B1 (ko) 2016-06-10 2022-04-29 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴 및 메트포르민의 병용물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1026793A (fr) * 1949-08-02 1953-05-04 American Cyanamid Co Procédé de préparation de sels de pénicilline
NL6803062A (cs) * 1967-03-10 1968-09-11
US3557094A (en) * 1968-01-05 1971-01-19 Pfizer & Co C Substituted alkyl esters of alpha-carboxy aryl penicillins
AT290728B (de) * 1968-09-28 1971-05-15 Takeda Chemical Industries Ltd Verfahren zur herstellung neuer penicilline

Also Published As

Publication number Publication date
JPS5512435B2 (cs) 1980-04-02
GB1386566A (en) 1975-03-12
DE2332840A1 (de) 1974-01-17
AT325206B (de) 1975-10-10
CA996548A (en) 1976-09-07
BE801588A (fr) 1973-12-28
JPS4925121A (cs) 1974-03-06
SE402916B (sv) 1978-07-24
CS168036B2 (cs) 1976-05-28
FR2190414A1 (cs) 1974-02-01
FR2190414B1 (cs) 1976-07-02
HU166029B (cs) 1974-12-28
US3925357A (en) 1975-12-09
AU5760073A (en) 1975-01-09
CH573435A5 (cs) 1976-03-15
AU469986B2 (en) 1976-02-26
PL92969B1 (cs) 1977-04-30

Similar Documents

Publication Publication Date Title
FR2190414B1 (cs)
JPS4994312A (cs)
JPS4893666A (cs)
FR2169033A1 (cs)
FR2193284B1 (cs)
FR2371068B1 (cs)
JPS516501Y2 (cs)
JPS5141919B2 (cs)
JPS4912994U (cs)
FR2212110A1 (cs)
FR2168478A1 (cs)
JPS4922113U (cs)
JPS499882U (cs)
JPS5323505Y2 (cs)
JPS4889709U (cs)
JPS4993194U (cs)
JPS4969120U (cs)
JPS4943466U (cs)
JPS4931510U (cs)
JPS4994683U (cs)
CH589027A5 (cs)
CH585821A5 (cs)
CH580689A5 (cs)
CH609244A5 (cs)
CH589593A5 (cs)

Legal Events

Date Code Title Description
BV The patent application has lapsed